Rhabdomyolysis and Renal Failure Associated with Gemfibrozil Monotherapy

Annals of Pharmacotherapy

Volumn 38, Issue 2, 2004, Pages 232-234

  Layne, Richard D ^a,b   Sehbai, Aasim S ^a   Stark, Linda J ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Acute kidney failure; Angiotensin converting enzyme inhibitors; Gemfibrozil; Rhabdomyolysis

Indexed keywords

ACETYLSALICYLIC ACID; CREATINE KINASE; CREATININE; GEMFIBROZIL; INSULIN; ISOPHANE INSULIN; LISINOPRIL; NICOTINIC ACID; SODIUM; SODIUM CHLORIDE;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DEHYDRATION; DRUG WITHDRAWAL; EXERCISE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOVOLEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MONOTHERAPY; MYALGIA; NAUSEA; PRIORITY JOURNAL; RHABDOMYOLYSIS; SODIUM URINE LEVEL; URINE OSMOLALITY; VOMITING;

ADULT; ANTILIPEMIC AGENTS; CREATININE; DIABETES MELLITUS, TYPE 1; EXERTION; GEMFIBROZIL; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; KIDNEY FAILURE, ACUTE; MALE; RHABDOMYOLYSIS;

EID: 1542333320     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D282     Document Type: Article

References (17)

1. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003;163:553-64.
2. Smith CC, Bernstein LI, Davis RB, Rind DM, Shmerling RH. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med 2003;163:688-92.
3. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90.
4. Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett 2002;128:159-68.
5. Pasternak RC, Smith SC, Bairez-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567-72.
6. Langer T, Levy RI. Acute muscular syndrome associated with administration of clofibrate. N Engl J Med 1968;279:856-8.
7. Atmaca H, Sayarlioglu H, Külah E, Demircan N, Akpolat T. Rhabdomyolysis associated with gemfibrozil-colchicine therapy. Ann Pharmacother 2002;36:1719-21. DOI 10.1345/aph.1C028
8. Gorriz JL, Sancho A, Lopez-Martin JM, Alcoy E, Catalan C, Pallardo LM. Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy. Nephron 1996;74:437-8.
9. Ward MW. Factors predictive of acute renal failure in rhabdomyolysis. Arch Intern Med 1988;148:1553-7.
10. Grossman RA, Hamilton RW, Morse BM, Penn AS, Goldberg M. Non-traumatic rhabdomyolysis and acute renal failure. N Engl J Med 1974;291:807-11.
11. Muscari A, Puddu GM, Puddu P. Lipid-lowering drugs: are adverse effects predictable and reversible? Cardiology 2002;97:115-21.
12. Albright RC. Acute renal failure: a practical update. Mayo Clin Proc 2001;76:67-74.
13. Knochel JP. Catastrophic medical events with exhaustive exercise: "white collar rhabdomyolysis." Kidney Int 1990;38:709-19.
14. Kamaliah MD, Sanjay LD. Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives. Singapore Med J 2001;42:368-72.
15. Magarian GJ, Lucas LM, Colley C. Gemfibrozil-induced myopathy. Arch Intern Med 1991;151:1873-4.
16. Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 1997;46:1206-10.
17. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.